EVIDENCE PROFILE / PUBLISHED
KPV
KPV is the tripeptide Lys-Pro-Val, a C-terminal fragment associated with alpha-MSH biology. No human administration study establishing safety or benefit was identified in the reviewed source set.
Evidence at a glance
- Human
- Not rated
- Animal/cell
- Not rated
- Approved medicine
- None foundScope: the sources reviewed.
Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.
PREPPY BOY ASKS
“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”
The catalogue name is a starting point, not proof of formulation or identity. Cell and animal research examines peptide transport, NF-kB-related inflammatory signaling, and intestinal or airway models.
Identity
KPV is the tripeptide Lys-Pro-Val, a C-terminal fragment associated with alpha-MSH biology.
Biological mechanism or research interest
Cell and animal research examines peptide transport, NF-kB-related inflammatory signaling, and intestinal or airway models.
Verified approved human uses
No approved human use was verified; FDA reports that it identified no human exposure data for nominated KPV drug products.
Investigational human evidence
No human administration study establishing safety or benefit was identified in the reviewed source set.
Popular claims versus demonstrated findings
Claims for inflammatory bowel disease, skin conditions, gut healing, or systemic inflammation are preclinical hypotheses, not demonstrated human outcomes.
Human versus animal or cell evidence
Published studies use human cell lines and mouse colitis models; cells derived from humans are still preclinical evidence.
Limitations and known risks
Human absorption, degradation, immunogenicity, impurities, route-specific exposure, interactions, and long-term safety are unknown.
